Literature DB >> 33419794

Chemoradiotherapy in Cancer Treatment: Rationale and Clinical Applications.

Kathrine S Rallis1,2, Thomas Ho Lai Yau2, Michail Sideris3.   

Abstract

Chemoradiotherapy (CRT) refers to the combined administration of both chemotherapy and radiotherapy as an anticancer treatment. Over the years, CRT has become an established treatment for a diverse range of locally advanced solid tumours. The rationale for CRT is based on the two concepts of spatial cooperation and in-field cooperation, whereby the end goal is to achieve synergistic antitumour effects from the combination of both treatment modalities. CRT offers notable patient survival benefits and local disease control without significant long-term toxicities. Although the enhancement of cytotoxic effects inevitably increases damage to normal tissues as well as tumour cells, if the damage to normal tissue is lesser than that to tumour cells, CRT is still deemed beneficial. Thus, the search to optimise dose, timings and fractionation of CRT is of particular interest. Considering the recent success achieved with anticancer immunotherapies including immune checkpoint inhibitors, the combination of CRT and immunotherapy has emerged as an exciting field of research with the potential for significant clinical benefit. This report outlines the rationale underlying CRT and discusses its advantages through clinical examples focusing on anal, cervical, non-small-cell lung cancer and bladder cancer. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Chemoradiotherapy; anal cancer; bladder cancer; cancer treatment; cervical cancer; chemotherapy; combination treatment; immunotherapy; non-small cell lung cancer; radiotherapy; review

Year:  2021        PMID: 33419794     DOI: 10.21873/anticanres.14746

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Long-term Response After Stopping Immunotherapy in a Patient With Metastatic Renal Cancer.

Authors:  Bogdan Haineala; Anca Zgura; Camelia Diaconu; Claudia Mehedintu; Xenia Bacinschi; Rodica Maricela Anghel
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

Review 2.  Molecular Genetics and Targeted Therapies for Paediatric High-grade Glioma.

Authors:  Kathrine S Rallis; Alan Mathew George; Anna Maria Wozniak; Carola Maria Bigogno; Barbara Chow; John Gerrard Hanrahan; Michail Sideris
Journal:  Cancer Genomics Proteomics       Date:  2022 Jul-Aug       Impact factor: 3.395

3.  Risk factors for oral mucositis during chemotherapy treatment for solid tumors: a retrospective STROBE-guided study.

Authors:  J-O Martins; M-M Borges; C-E Malta; A-C Carlos; A-A Crispim; J-F Moura; I-J Fernandes-Lima; P-G Silva
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2022-07-01

4.  CD44 Receptor-Mediated/Reactive Oxygen Species-Sensitive Delivery of Nanophotosensitizers against Cervical Cancer Cells.

Authors:  Jieun Yoon; Howard Kim; Young-Il Jeong; Hoe Saeng Yang
Journal:  Int J Mol Sci       Date:  2022-03-25       Impact factor: 5.923

Review 5.  Radiation-induced prodrug activation: extending combined modality therapy for some solid tumours.

Authors:  Nicola J Farrer; Geoff S Higgins; Ian H Kunkler
Journal:  Br J Cancer       Date:  2022-02-25       Impact factor: 9.075

Review 6.  Current treatments for non-small cell lung cancer.

Authors:  Qianqian Guo; Liwei Liu; Zelong Chen; Yannan Fan; Yang Zhou; Ziqiao Yuan; Wenzhou Zhang
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.